{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:30:32Z","timestamp":1783693832231,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T00:00:00Z","timestamp":1435276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T00:00:00Z","timestamp":1435276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Diabetic macular oedema (DMO) is a leading cause of blindness in working-age adults. Slow-release, nonbioerodible fluocinolone acetonide (FAc) implants have shown efficacy in the treatment of DMO; however, the National Institute for Health and Care Excellence recommends that FAc should be used in patients with chronic DMO considered insufficiently responsive to other available therapies only if the eye to be treated is pseudophakic. The goal of this analysis was to examine treatment outcomes in phakic patients who received 0.2\u2009<jats:italic>\u03bc<\/jats:italic>g\/day FAc implant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This analysis of the phase 3 FAME (Fluocinolone Acetonide in Diabetic Macular Edema) data examines the safety and efficacy of FAc implants in patients who underwent cataract extraction before (cataract before implant (CBI) group) or after (cataract after implant (CAI) group) receiving the implant. The data were further examined by DMO duration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Best corrected visual acuity (BCVA) after 36 months was comparable in the CAI and CBI groups. Both the percentage of patients gaining \u22653 lines of vision and mean change in BCVA letter score were numerically greater in the CAI group. In addition, most patients who underwent cataract surgery experienced a net gain in BCVA from presurgery baseline as well as from original study baseline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These data support the use of 0.2\u2009<jats:italic>\u03bc<\/jats:italic>g\/day FAc implants in phakic as well as in pseudophakic patients. These findings will serve as a pilot for design of future studies to evaluate the potential protective effect of FAc implants before cataract surgery in patients with DMO and cataract.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/eye.2015.98","type":"journal-article","created":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T09:31:29Z","timestamp":1435311089000},"page":"1173-1180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants"],"prefix":"10.1038","volume":"29","author":[{"name":"on behalf of the FAME study group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F G","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Eter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Menchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Ruiz Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Dugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Lotery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,26]]},"reference":[{"key":"BFeye201598_CR1","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/S0161-6420(84)34102-1","volume":"91","author":"R Klein","year":"1984","unstructured":"Klein R, Klein BE, Moss SE, Davis MD, DeMets DL . The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984; 91: 1464\u20131474.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR2","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0161-6420(98)96025-0","volume":"105","author":"SE Moss","year":"1998","unstructured":"Moss SE, Klein R, Klein BE . The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998; 105: 998\u20131003.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2008.10.001","volume":"54","author":"N Bhagat","year":"2009","unstructured":"Bhagat N, Grigorian RA, Tutela A, Zarbin MA . Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009; 54: 1\u201332.","journal-title":"Surv Ophthalmol"},{"key":"BFeye201598_CR4","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013\u20132022.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR5","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1016\/j.ophtha.2012.08.022","volume":"119","author":"MJ Elman","year":"2012","unstructured":"Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012; 119: 2312\u20132318.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR6","unstructured":"Mitchell P, RESTORE extension study group. 2-year safety and efficacy outcome of ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (DME): an interim analysis of the Restore Extension Study. Presented at 2012 ARVO Annual Meeting; 6\u20139 May 2012; Fort Lauderdale, FL (poster 4667)."},{"key":"BFeye201598_CR7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789\u2013801.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR8","unstructured":"Boyer DS, Sy J, Chen Rundle A, Hopkins JJ, Erlich JS RISE and RIDE Research Group. Ranibizumab (anti-VEGF) for vision loss due to diabetic macular edema \u2013 results of two phase III randomized trials. Presented at American Diabetes Association 71st Scientific Sessions; 24\u201328 June 2011; San Diego, CA (abstract 0132-LBOR)."},{"key":"BFeye201598_CR9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615\u2013625.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR10","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.ophtha.2009.04.023","volume":"116","author":"QD Nguyen","year":"2009","unstructured":"Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2009; 116: 2175\u20132181 e1.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/archophthalmol.2012.393","volume":"130","author":"R Rajendram","year":"2012","unstructured":"Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130: 972\u2013979.","journal-title":"Arch Ophthalmol"},{"key":"BFeye201598_CR12","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121: 2247\u20132254.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR13","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","volume":"130","author":"SB Bressler","year":"2012","unstructured":"Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol 2012; 130: 1153\u20131161.","journal-title":"Arch Ophthalmol"},{"key":"BFeye201598_CR14","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/j.ophtha.2013.02.018","volume":"120","author":"DG Callanan","year":"2013","unstructured":"Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120: 1843\u20131851.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR15","unstructured":"Boyer DS, MEAD Study Group. Phase 3, multicenter, masked, randomized, sham-controlled trials to assess the safety and efficacy of 700 \u03bcg and 350 \u03bcg dexamethasone posterior segment drug delivery system (DEX PS DDS\u00ae) in the treatment of patients with diabetic macular edema (DME). Presented at American Academy of Ophthalmology Annual Meeting; 16\u201319 November 2013; New Orleans, LA."},{"key":"BFeye201598_CR16","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904\u20131914.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR17","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S0161-6420(10)01231-5","volume":"118","author":"PA Campochiaro","year":"2011","unstructured":"Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118: e2.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR18","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"PA Campochiaro","year":"2012","unstructured":"Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119: 2125\u20132132.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR19","unstructured":"ILUVIEN [summary of product characteristics] Hampshire, UK: Alimera Sciences Limited, 2013."},{"key":"BFeye201598_CR20","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.ophtha.2008.06.015","volume":"115","author":"Diabetic Retinopathy Clinical Research Network","year":"2008","unstructured":"Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal\/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447\u20131449 1449.e1\u2013e10.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1076\/soph.18.3.103.29805","volume":"18","author":"U Menchini","year":"2003","unstructured":"Menchini U, Cappelli S, Virgili G . Cataract surgery and diabetic retinopathy. Semin Ophthalmol 2003; 18: 103\u2013108.","journal-title":"Semin Ophthalmol"},{"key":"BFeye201598_CR22","first-page":"912","volume":"118","author":"RA Mittra","year":"2000","unstructured":"Mittra RA, Borrillo JL, Dev S, Mieler WF, Koenig SB . Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus. Arch Ophthalmol 2000; 118: 912\u2013917.","journal-title":"Arch Ophthalmol"},{"key":"BFeye201598_CR23","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/archopht.117.12.1600","volume":"117","author":"EY Chew","year":"1999","unstructured":"Chew EY, Benson WE, Remaley NA, Lindley AA, Burton TC, Csaky K et al. Results after lens extraction in patients with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report Number 25. Arch Ophthalmol 1999; 117: 1600\u20131606.","journal-title":"Arch Ophthalmol"},{"key":"BFeye201598_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0161-6420(99)90148-3","volume":"106","author":"JG Dowler","year":"1999","unstructured":"Dowler JG, Sehmi KS, Hykin PG, Hamilton AM . The natural history of macular edema after cataract surgery in diabetes. Ophthalmology 1999; 106: 663\u2013668.","journal-title":"Ophthalmology"},{"key":"BFeye201598_CR25","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/bjo.83.9.1036","volume":"83","author":"A Zaczek","year":"1999","unstructured":"Zaczek A, Olivestedt G, Zetterstrom C . Visual outcome after phacoemulsification and IOL implantation in diabetic patients. Br J Ophthalmol 1999; 83: 1036\u20131041.","journal-title":"Br J Ophthalmol"},{"key":"BFeye201598_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/eye.1995.61","volume":"9","author":"JG Dowler","year":"1995","unstructured":"Dowler JG, Hykin PG, Lightman SL, Hamilton AM . Visual acuity following extracapsular cataract extraction in diabetes: a meta-analysis. Eye (Lond) 1995; 9: 313\u2013317.","journal-title":"Eye (Lond)"},{"key":"BFeye201598_CR27","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/jamaophthalmol.2013.2313","volume":"131","author":"CW Baker","year":"2013","unstructured":"Diabetic Retinopathy Clinical Research Network Authors\/Writing Committee, Baker CW, Almukhtar T, Bressler NM, Glassman AR, Grover S et al. Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. JAMA Ophthalmol 2013; 131: 870\u2013879.","journal-title":"JAMA Ophthalmol"},{"key":"BFeye201598_CR28","doi-asserted-by":"crossref","unstructured":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796\u20131806.","DOI":"10.1001\/archopht.1985.01050120030015"},{"key":"BFeye201598_CR29","unstructured":"National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271). September 2013. Available from \n                    http:\/\/www.nice.org.uk\/guidance\/ta301\/resources\/diabetic-macular-oedema-fluocinolone-acetonide-intravitreal-implant-rapid-review-of-ta271-final-appraisal-determination-document2\n                    \n                   (accessed 31 October 2014)."},{"key":"BFeye201598_CR30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/eye.1996.171","volume":"10","author":"RJ Antcliff","year":"1996","unstructured":"Antcliff RJ, Poulson A, Flanagan DW . Phacoemulsification in diabetics. Eye (Lond) 1996; 10: 737\u2013741.","journal-title":"Eye (Lond)"},{"key":"BFeye201598_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/112067219900900103","volume":"9","author":"SA Sadiq","year":"1999","unstructured":"Sadiq SA, Sleep T, Amoaku WM . The visual results and changes in retinopathy in diabetic patients following cataract surgery. Eur J Ophthalmol 1999; 9: 14\u201320.","journal-title":"Eur J Ophthalmol"},{"key":"BFeye201598_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1136\/bjo.76.4.221","volume":"76","author":"A Pollack","year":"1992","unstructured":"Pollack A, Leiba H, Bukelman A, Oliver M . Cystoid macular oedema following cataract extraction in patients with diabetes. Br J Ophthalmol 1992; 76: 221\u2013224.","journal-title":"Br J Ophthalmol"},{"key":"BFeye201598_CR33","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/S0886-3350(02)01243-9","volume":"28","author":"H Funatsu","year":"2002","unstructured":"Funatsu H, Yamashita H, Noma H, Shimizu E, Mimura T, Hori S . Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy. J Cataract Refract Surg 2002; 28: 1355.","journal-title":"J Cataract Refract Surg"}],"updated-by":[{"DOI":"10.1038\/eye.2015.145","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,9,10]],"date-time":"2015-09-10T00:00:00Z","timestamp":1441843200000}}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye201598.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye201598","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye201598.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:27:17Z","timestamp":1684430837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye201598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,26]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["BFeye201598"],"URL":"https:\/\/doi.org\/10.1038\/eye.2015.98","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/eye.2015.145","asserted-by":"object"}]},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,26]]},"assertion":[{"value":"1 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2015","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YY: honoraria, advisory board: Alimera Sciences, Allergan, Alcon, Bayer, Novartis, Thrombogenics; consultancy: Alimera Sciences, Allergan; CB: honoraria: Novartis; commercial funding for clinical trial recruitment via Bristol Eye Hospital: Alimera Sciences; research funding for clinical trials work via Bristol Eye Hospital: Bayer; FGH: research funding, consultancy, grants, honoraria: Alimera Sciences, Allergan, Novartis; NE: research funding, speakers bureau, honoraria, advisory board: Novartis, Bayer, Allergan; speakers bureau, honoraria: Heidelberg Engineering; advisory board: Bausch and Lomb; research funding, advisory board: Alimera Sciences; MW: honoraria, advisory board: Alimera Sciences; CB: advisory board: Alimera Sciences; SK: consultancy, honoraria: Alimera Sciences, Allergan, Genentech\/Roche, Regeneron, speakers bureau: Allergan, Genentech\/Roche, Regeneron; PD: consultancy, honoraria: Alimera Sciences, Allergan, Alcon; AL: research funding, honoraria, advisory committee: Alimera Sciences; JMRM and UM: nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}